Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus gemcitabine and cisplatin versus gemcitabine plus cisplatin after palliative resection for biliary tract cancer
ChiCTR2000036083Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Sep 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab, gemcitabine and cisplatin in biliary cancer, gallbladder cancer and cholangiocarcinoma (CCA) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Overall survival. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
sintilimabgemcitabinecisplatin
03
Conditions
biliary cancergallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2000036083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036083.